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Abstract
Purpose This study aims to evaluate the number of cases
of occult uterine malignancies in all LASH surgeries at the
MIC clinic (Berlin) and to verify how the operative tech-
nique affects the prognosis of the disease.
Methods Data of 10,731 patients who underwent a stan-
dardized LASH surgery with electric power morcellation
between 1998 and April 30, 2014 were retrospectively
analyzed. Main indication for LASH was symptomatic
uterine myomas (81.3 %).
Results No intra-operative complication was caused by
use of a morcellator. In total, six sarcomas (0.06 %), in-
cluding four endometrial stromal sarcomas (0.04 %) two
leiomyosarcomas (0.02 %), and eight endometrial cancers
(0.07 %) were documented. This amounts to a very low
uterine malignancy rate of 0.13 %. Median follow-up pe-
riod for all six patients with sarcoma and seven patients
with endometrial cancer was 65.58 months (13–169). No
recurrence was reported for the patients with endometrial
cancer and five sarcoma patients in the comprehensible
follow-up period. One patient died 13 months after LASH
surgery due to the diagnosed leiomyosarcoma with peri-
toneal carcinomatosis and bone metastases.
Conclusion In 10,731 morcellated uteri during LASH
only 0.06 % sarcoma and 0.07 % endometrial carcinoma
were detected. All patients should be informed about the
rare possibility of a malignant disease during pre-operative
counseling. With a timely follow-up surgery according to
the oncologic guidelines, our data suggest a very good
prognosis in terms of survival after LASH with morcella-
tion of malignant tumors in the uterus.
Keywords Laparoscopic supracervical hysterectomy 
Morcellation  Uterine sarcoma  Endometrial cancer
Introduction
In present-day gynecology, hysterectomy belongs to the
standard procedures and is one of the most commonly
performed surgeries. The first laparoscopic hysterectomy
was performed by Harry Reich [1] 25 years ago in 1989.
Since 1990 the laparoscopic supracervical approach to
hysterectomy has evolved both in Europe and the US [2–5].
Advancements of endoscopic instruments and of operational
techniques have meanwhile led to a significant reduction in the
number of abdominal hysterectomies. This is because more
vaginal hysterectomies in combination with laparoscopy,
showing a lower rate of complications, are performed [6, 7].
During laparoscopic assisted vaginal hysterectomy
(LAVH) the uterus can be morcellated and removed
vaginally after respective laparoscopic preparation. With-
out indications for removal of the cervix, the cervical
stump can be retained and the corpus uteri is removed via
laparoscopic morcellation using an electronic morcellator
during laparoscopic supracervical hysterectomy (LASH).
Because of this procedure, the necessity for abdominal
hysterectomy very rarely arises at the MIC clinic Berlin,




1 Klinik fu¨r Minimal Invasive Chirurgie, Kurstraße 11,
14129 Berlin-Zehlendorf, Germany
2 Clinic of Gynecology, Obstetrics and Gynecological
Oncology, University Hospital for Gynecology, Pius-Hospital
Oldenburg, School of Medicine and Health Sciences, Carl
von Ossietzky University, Oldenburg, Germany
123
Arch Gynecol Obstet (2015) 292:665–672
DOI 10.1007/s00404-015-3696-z
However, the American Association of Gynecologic
Laparoscopists (AAGL) stated that, in case of known or
suspected uterine malignancy, morcellation is contraindi-
cated [8]. Due to safety concerns—more specifically, the
potential for dissemination of occult uterine cancer that
may occur via morcellation during hysterectomy and my-
omectomy leading to a poorer prognosis—the Food and
Drug Administration (FDA) recently issued a statement
discouraging the use of electromechanical morcellation for
hysterectomy and myomectomy in most women with
uterine myoma [9].
As patient safety and patient satisfaction are the main
goals of all new developments in endoscopic surgery, the
AAGL convened a tissue extraction task force to examine
the propriety of this ban. Based on existing literature, the
data concerning the frequency of malignancies during
morcellation needs to be updated in order to confirm that
the use of morcellation during hysterectomy and my-
omectomy does not offer a significant patient disadvantage
versus open surgery in the rare occurrence of malignancy
being discovered post-operatively or for the development
of new concepts to improve patient safety [10].
Endometrial cancer is the most common gynecologic
malignancy in the US, with over 50,000 new cases and
almost 8600 related deaths each year [11]. The median age
of diagnosis is 66 and very often abnormal bleeding is a
first sign of the disease [12]. Leiomyosarcomas and other
uterine sarcomas are very rare, accounting for up to 7–8 %
of all uterine cancers [13]. The median age at which uterine
leiomyosarcoma is diagnosed is usually between 47 and
56 years [14].
The aim of this study was to evaluate the number of
cases of occult uterine malignancies in all LASH op-
erations at the MIC clinic and to verify how the operational
technique affects the prognosis of the disease by tracking
all patient files.
Materials and methods
Patients and data collection
In a retrospective study, the number of cases of occult
uterine malignancies in LASH operations was evaluated
for the period from 1998 to April 30, 2014. During this
time, a total of 10,731 LASH surgeries were performed at
the MIC clinic. The exact figure of malignant uterine
findings during LASH surgery was available due to an
inaugural dissertation from 2005 which recorded all his-
tological findings of 1706 LASH surgeries performed be-
tween 1998 and October 2003 [15]. Therefore, patient data
for all patients with malignancy till October 2003 could be
collected and analyzed as currently valid. From November
to December 2003 no malignant findings were recorded in
any LASH surgery. In 2004 a questionnaire for a mutual
cancer registry was introduced, which obliges every clinic
in 6 German federal states to report each malignant finding.
Therefore, all cases of endometrial carcinoma, uterine
sarcoma, including leiomyosarcoma, were available for the
entire period of this study. All patient files were collected.
Via telephone the treating gynecologist was asked about
the time of the last examination, possible recurrences and
therapies of the patient.
Our data relate to endometrial stromal sarcoma, en-
dometrial cancer, leiomyosarcoma and carcinosarcoma.
Smooth muscle tumors with uncertain malignant poten-
tial [atypical leiomyomas, smooth muscle tumors of
undetermined malignant potential (STUMP), prolif-
erative leiomyomas and high-grade proliferative
leiomyomas] are not recorded in the cancer registry and
were not evaluated before 2004 [15]. Therefore, these
tumors could not be evaluated in this retrospective study.
Findings concerning atypical myomas and tumors of
undetermined malignant potential were of incidental
nature. Three cases, reported in this study, concerning
atypical myomas and tumors of undetermined malignant
potential are only identified due to further documented
follow-up surgery as part of different surveys or later
documented malignancy. They are also included in the
discussion. No Institutional Review Board (IRB) ap-
proval was obtained.
Main indication for LASH were the symptomatic uterine
myomas (81.3 %) [7, 16].
Premalignant or malignant findings in the area of the
cervix and the corpus uteri were considered as con-
traindications for laparoscopic supracervical hysterectomy.
All patients were pre-operatively vaginally examined
by the surgeon including a speculum of the cervix and a
vaginal sonography was also conducted. In case of
sonographic endometrial abnormalities, a diagnostic
hysteroscopy and endometrial curettage was performed
before LASH. The endometrial thickness was not obli-
gatory documented. A cervical PAP test, not older than
1 year, was available for every patient.
Surgical procedure
The previously published LASH operation technique with
electric power morcellation was standardized and remained
consistent throughout the observation period [7, 16, 17].
Surgery was performed by 4 surgeons. High patient satis-
faction [7–9], low complication rates [7, 16] and very low
conversion rates to abdominal hysterectomies have already
been reported [7, 16, 17].
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Pathology and follow-up
The material was immediately fixed in 7.5 % buffered
formaldehyde. After fixation for minimally 24 h all cores
were macroscopically examined by two experienced gy-
necological pathologists according to color, consistence,
necrosis and margins. All suspicious cores were separated.
Photo documentation was done.
Cut sections (4–5 lm) were stained in hematoxylin–
eosin in a fully automatic stainer (Symphonie Fa Roche).
Microscopy was done using an Olympic BX51.
Immunohistochemistry was obtained by using the Bench
Mark XT (Fa Roche/Ventana). All sarcoma and diagnoses
were re-examined and confirmed in a German pathologic
reference-center.
The key diagnostic microscopical criteria for
leiomyosarcomas were proliferative or mitotic activity,
nuclear and cytological atypias and findings of geographic
necroses. In case of endometrial stromal sarcoma, enrich-
ment of small uniform cells was detected microscopically.
Endometrial stromal morphology was still discernible and
resembles proliferation phase stroma. Significant atypias or
conspicuous pleomorphism was not detectable. In case of
endometrial stromal sarcoma CD 10 was found positive
during immunohistochemistry.
Potentially malignant myomas were defined as epithelial
leiomyomas larger than 6 cm. Less than 4 mitoses/10 HPF
(high power fields) and mild atypias may happen.
Statistics
For the parameters age and uterus weight the mean was
calculated. Data were analyzed using Windows-Excel
(Microsoft 2010). Mean values were calculated and shown
with standard deviations and 95 % CI.
Results
Malignancies at time of surgery
Patient data from 10,731 LASH operations with electric
power morcellation were evaluated. The indication for
surgery in 8720 patients (81.3 %) was uterine myomas, in
1015 patients (9.4 %) bleeding disorder, in 361 patients
(3.4 %) suspected uterine adenomyosis and in 635 patients
(5.9 %) uterine prolapse. In case of uterine prolapse LASH
was combined with a sacropexy of the cervical stump.
No intra-operative complication was caused by the use
of the morcellator. In total, six sarcomas (0.06 %), in-
cluding two leiomyosarcomas (0.02 %) and eight en-
dometrial cancers (0.07 %) were documented. For detailed
data see Table 1.
Out of the six sarcomas, four patients exhibited a low-
grade endometrial stromal sarcoma.
In two patients a leiomyosarcoma was detected. Both
patients with leiomyosarcoma were 49 years old and pre-
sented significantly enlarged uteri, weighting 1.000 and
567 g, respectively.
Median age, weight and height of all patients with
uterine malignomas including endometrial cancer and
sarcomas can be found in Table 2.
In 8720 cases of diagnosed uterine myomas serving as
indication for LASH surgery only 4 patients were ulti-
mately found to have a histological proven sarcoma: this
amounts to a sarcoma rate of 0.05 %. In two patients
bleeding disorders were the indication for LASH. One
month before LASH one of these two patients underwent
hysteroscopy and endometrial curettage without any sign
of malignancy. The second patient did not undergo a
hysteroscopy and endometrial curettage due to unsuspi-
cious findings during pre-operative endometrial
sonography.
Eight endometrial cancers were found, one endometrial
cancer in situ (a noninvasive endometrial lesion with ser-
ous differentiation), one adenocarcinoma, located in an
endometrial polyp, one undifferentiated endometrial car-
cinoma and five endometrioid adenocarcinomas. However,
except for the undifferentiated endometrial carcinoma, the
tumor was in an early stage (stage I—FIGO—UICC).
Recurrences and follow-up surgery
Follow-up data for all six patients with sarcoma and seven
out of eight patients with endometrial cancer are available.
Median follow-up period was 65.58 months (13–169). All
patients with sarcoma and six patients with endometrial
cancer underwent re-exploration.
There is no data available for the patient with en-
dometrial cancer in situ with regard to recurrences, follow-
up surgery or death. No recurrence was reported for the
Table 1 Malignant histological uterine findings after LASH
n %
Uterine malignancies 13 0.13
Sarcoma 6 0.06
Low-grade endometrial stromal sarcoma 4 0.04
Leiomyosarcoma 2 0.02
Endometrial cancer 8 0.07
Endometrial cancer in situ 1 0.01
Adenocarcinoma located in a polyp 1 0.01
Undifferentiated endometrial carcinoma 1 0.01
Endometrioid adenocarcinoma 5 0.05
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remaining seven patients with endometrial cancer in a
median follow-up period of 74 months (16–169 months).
For seven patients with endometrial cancer, as
documented above, they underwent follow-up surgery
32 days (11–56 days) after LASH. In all seven patients a
cervical extirpation with bilateral salpingo-ovarectomy and
a ‘‘pelvic wash’’ was performed: no residual tumor or tu-
mor cells were found (see Table 3).
Two patients underwent an additional pelvic lym-
phadenectomy (see Table 3). In one patient 20 nontumor-
ous lymph nodes were removed. In the patient with
undifferentiated endometrial carcinoma five lymph node
metastases were found. This patient received further
treatment in an oncological center. The latest medical in-
formation about this patient is at 61 months post-LASH: at
this time the patient was free from recurrence. The latest
Table 2 Demographic data of
patients with endometrial cancer
and sarcomas





Mean years ± SD 51.4 ± 6.1 48.7 ± 5.7 50.2 ± 5.8
Range 51.6–53.2 48.5–49.9 50.1–51.1
Patients height
Mean cm ± SD 171.4 ± 7.0 168.8 ± 3.5 170.4 ± 5.7
Range 171.3–175.3 168.7–173.1 170.3–173.2
Patients weight
Mean g ± SD 88.9 ± 31.6 75.2 ± 12.9 83.0 ± 25.6
Range 88.2–90.8 74.8–77.1 82.6–84.4

















1 57 43.6 16.03.2000 300 Adenocarcinoma in polyp, pT 1a 04/2014 169 No
27.03.2000 No tumor in cervix, adnexa, lavage
2 60 29.7 25.01.2001 84 Endometrioid adenocarcinoma G1 07/2013 151 No
12.02.2001 No tumor in cervix, adnexa, lavage, pT
1b
3 50 21.6 26.09.2000 150 Endometrial cancer in situ, pT 1a No information
available
4 45 19.7 13.05.2004 400 Undifferentiated endometrial cancer,
pT 1a/b, N1 (5/17), MX, V0, L0;
FIGO III C
06/2009 61 No
03.06.2004 No tumor in cervix, adnexa, 5 positive
lymph nodes
5 46 27.9 29.07.2008 157 Endometrioid adenocarcinoma pT1a
G2
11/2009 16 No





6 46 50.0 03.12.2008 230 Endometrioid adenocarcinoma, pT1a
G1–2
05/20013 53 No
02.01.2009 No tumor in cervix, adnexa, lavage and
28 lymph nodes
7 58 29.6 01.03.2001 50 Endometrioid adenocarcinoma, pT1b
G1
05/2014 38 No
12.04.2011 No tumor in cervix, adnexa, lavage
8 49 20.7 06.12.2011 26 Endometrioid adenocarcinoma, pT1a
G1
05/2014 30 No
31.01.2012 No tumor in cervix, adnexa, lavage
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medical information about the patient with the 20 nontu-
morous lymph nodes is at 16 months post-LASH: no signs
of recurrence were present at that time (see Table 3).
Follow-up surgery in case of sarcoma was done 51 days
(2–91) after LASH: no residual tumor or tumor cells were
found. In one obese patient with leiomyosarcoma a peri-
toneal carcinomatosis was detected during laparotomy
10 months post-LASH. This patient died 13 months after
LASH surgery due to the diagnosed leiomyosarcoma with
peritoneal carcinomatosis and bone metastases. Two
months after LASH this patient underwent a laparoscopic
cervical stump extirpation without intra-operative signs of
metastasis. Eleven months after primary surgery peritoneal
metastasis and bone metastases were detected
radiologically.
One patient with leiomyosarcoma (follow-up of
137 months) and four patients with endometrial stromal
sarcoma were still alive when last information was avail-
able with a follow-up period of 22, 57, 36 and 36 months,
respectively. All patients underwent follow-up surgery: no
histological abnormalities were detected in the extirpated
cervix and adnexa. The patient with endometrial cancer
and additional stromal sarcoma also underwent cervical
and adnexal extirpation: no histological abnormalities were
detected, and 3 years after operation no recurrences were
present. For the past 3 years there is no further information
available concerning this patient. In one patient with en-
dometrial stromal sarcoma no signs of recurrence were
detected 26 months post-surgery. From May 2010 onwards
there is no further information available with regard to this
patient. See also Table 4.
Besides above malignant findings, histological abnor-
malities were detected in three other patients. In 2001 a
uterus weighting 180 g was removed in a 51-year-old pa-
tient: histological examination revealed a mesenchymal
neoplasia, a UTROSCT-tumor (uterine tumor resembling
ovarian sex cord tumor). During removal of the cervix
6 months later no remnants of the tumor were detected. At
the time of follow-up examination in January 2013 the
patient was free of recurrence.
No further data are available for one patient with a
450 g uterus with potential malignant myoma after Fe-
bruary 2002: 17 months post-surgery this patient was free
from complaints.
In 2001 one 55-year-old patient with a 230 g uterus was
diagnosed with high-grade proliferative myoma, a benign,
cellular leiomyoma without necrosis or mitotic activity
\10 per 10 HPF. Due to abdominal problems she under-
went a laparoscopy in 2012 with tumor extirpation at the
anterior abdominal wall. Histology revealed a benign en-
dometrial stromal tumor based on the type of tumor mar-
gin. Five months later in March 2013 (12 years post
primary LASH), a recurrent tumor was removed and a low-
grade endometrioid stromal sarcoma was detected histo-
logically. This tumor represents a completely different
entity than the one detected in 2001 and it remains ques-
tionable if both are related. In May 2014 (14 months after
diagnosis) and after a letrozol therapy this patient was free
of recurrence and complaints.
Discussion
The presented data show a very low uterine malignancy
rate in patients undergoing LASH, with the most aggres-
sive tumors with a bad prognosis occurring even less
commonly. Leiomyosarcoma is a very aggressive and rare
cancer and only has a small part in the group of malig-
nancies in LASH. This and other uterine sarcomas account
for up to 7–8 % of all uterine cancers [13]. The FDA es-
timates that 0.3 % of all women undergoing hysterectomy
or myomectomy for the treatment of fibroids are found to
have an unsuspected uterine sarcoma [9]. In our study only
six sarcomas [0.06 % ± 2.4 (0.054–0.057)], including two
leiomyosarcomas [0.02 % ± 1.4 (0.018–0.019)], were
found. Correspondingly the probability of accidently
morcellating a sarcoma is very low. Theben et al. found an
unexpected malignancy rate of 0.25 % (n = 4 out of 1584
patients) after LASH. Two patients were diagnosed with
endometrial cancer and leiomyosarcoma. Yet in the short
period of the study (28–52 months) these patients remained
free of recurrence after treatment [18].
Five out of six patients with sarcomas are still alive with
a follow-up period of 58.4 months. To our knowledge, only
one patient with a leiomyosarcoma died 13 months after
surgery. The progression-free survival in leiomyosarcoma
is normally 1.1 years, median survival is 3.6 years and
5-year survival rates for stage I tumors is 57 % for
leiomyosarcoma [19]. Thus the death of one of our patients
with leiomyosarcoma confirms the bad prognosis associ-
ated with this tumor. However, it is questionable which
effect morcellation has on the progress of the disease or
which progress would have been observed after abdominal
hysterectomy or no operation in case of an enlarged uterus
weighting over 1000 g.
In case of endometrial cancer, no related death or re-
currence after LASH with morcellation of the uterus and a
timely follow-up surgery was found. Only the post-surgical
data of one patient with endometrial cancer, in fact the one
patient with the best prognosis of all patients, is missing. In
summary our data suggest a very good prognosis in terms
of survival after LASH with morcellation of malignant
tumors in the uterus, if a timely follow-up surgery ac-
cording to the oncologic guidelines is performed.
The four patients with stromal sarcoma had a very good
prognosis. Although there are only few cases in summary
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our results show better prognosis in case of endometrial
stromal sarcoma compared to leiomyosarcoma.
Despite preliminary examination, including vaginal
sonography, eight endometrial carcinomas were only de-
tected after the histopathological examination of the LASH
specimen. In case of suspicious sonography during pre-
operative diagnostic investigation diagnostic hysteroscopy
and endometrial curettage was conducted before LASH.
Four patients with endometrial carcinomas underwent
an endometrial curettage and diagnostic hysteroscopy be-
fore LASH and showed no signs of malignancy. This
demonstrates that due to known error rates even for
curettage and sonography there will always be individual
cases with unexpected malignancies [20–23].
In this retrospective study, all morcellated uterine my-
omas occurring in the study period were recorded. As
smooth muscle tumors with uncertain malignant potential
(atypical leiomyomas, smooth muscle tumors of undeter-
mined malignant potential (STUMP), proliferative
leiomyomas and high-grade proliferative leiomyomas)
were not included in this study, patients with undetected
pre-malignancies are probably left out unconsidered. These
patients might expect recurrences.
No data are available concerning the effect of electric
morcellation on recurrence and probable formation of
sarcomas in case of these tumors. As indicated by this
study and further literature these cases should be system-
atically evaluated and re-examined. If possible the progress
should be recorded in specific registries in the same manner
as malignant diagnoses are already documented.
STUMP-tumors have a low recurrence rate, ranging
from 7.2 % [24] to 27 % [25]. However, there is the pos-
sibility that despite their uncertain nature, STUMPs can
exhibit metastatic activity, recur as STUMPs or undergo
malignant transformation to leiomyosarcomas [24, 26].
Therefore, in all cases of histological proven atypical
myomas or STUMP-tumors a diagnostic laparoscopy either
in case of clinical signs of recurrence or at the latest 1 year
post-surgery, is recommended at the MIC clinic. In the few
cases 1 year post-surgery a diagnostic laparoscopy was
performed to exclude tumor recurrence. However, in our
study no recurrence was reported after LASH with pre-
ceding atypical myomas or STUMP-tumors. In most cases
these tumors are benign. At present day there are no factors
known to predict the risk of recurrence in those entities.
All patients need to be informed about the rare possi-
bility of a malignant disease and alternative treatment
methods during pre-operative counseling. Recurrence and
long distant metastases are significantly rarer. However,
they develop much later as in case of leiomyosarcomas,
which occur soon after surgery. Recently a retrospective,
multi-institution study of patients with stage I–II uterine
leiomyosarcoma whose uteri were removed intact, found
recurrence in the first 2.5 years after diagnosis in 71.8 % of
all patients [27]. Even 20 years post-surgery recurrent
disease is possible [28]. In case of post-operative














1 49 27.4 04.12.2002 567 Leiomyosarcoma 05/2014 137 No
06.12.2002 No tumor in cervix, adnexa,
lavage
2 44 22.1 25.03.2008 106 Endometrial stromal sarcoma
(low grade)
05/2010 26 No
14.07.2008 No tumor in cervix, adnexa,
lavage
3 43 29.0 17.06.2008 590 Endometrial stromal sarcoma
(low grade)
03/2014 57 No
02.10.2008 No tumor in cervix, adnexa
lavage
4 48 21.2 13.05.2008 90 Endometrial stromal sarcoma
(low grade)
05/2011 36 No
12.08.2008 No tumor in cervix, adnexa,
lavage
5 49 33.7 04.11.2008 1000 Leiomyosarcoma 13 Yes




6 59 24.8 15.01.2009 440 Endometrial stromal sarcoma 12/2012 36 No
26.02.2009 No tumor in cervix, adnexa,
lavage
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malignancy finding, a timely follow-up surgery according
to the oncologic guidelines is necessary. Essentially in case
of such rare incidences, the prognosis is difficult to predict.
Only after applying an abundant lavage at the end of
laparoscopy after removal of all abdominal remnants of
myomas and tissues and careful control of the area of op-
eration as well as the middle and upper abdomen the sur-
gery is finished. This way the risk of complications and
bleedings and remaining tissue in the abdomen are tried to
be excluded.
Due to the lower malignancy rate shown in our study as
compared to the data presented by the FDA, we conclude
that the abandonment of morcellation is not necessary. The
need for morcellation of every uterus in retrieval pouches
still has to be proven in further studies.
The FDA discouraged the use of laparoscopic morcel-
lation for hysterectomy and myomectomy [9] based on
very few mostly single-institution and retrospective studies
(8 publications) with an inadequately low number of pa-
tients (more than half contain fewer than 1000 patients). In
our view along with the task force’s analysis [10] the
malignancy rate, to be actually expected, during morcel-
lation of uteri or myomas, derived from these studies, is
inadequately proven.
It is of positive value that the FDA has put this problem on
the agenda. However, the consequence of this recommen-
dation for all patients with myomas disregards many of the
scientific proven advantages of minimal invasive surgery.
The use of specimen retrieval pouches represents an
option; it is however unclear to decide which cases are
intra-operatively doubtful, or this should be a general
measurement. Also further research on the use of specimen
retrieval pouches during morcellation is necessary to ex-
amine the possibly increasing complication rate concerning
injuries to adjacent organs. The Task force states: ‘‘The use
of morcellation within specimen retrieval pouches for
containment of benign or malignant uterine tissue requires
significant skill and experience, and the use of specimen
retrieval pouches should be investigated further for safety
and outcomes in a controlled setting’’ [10].
All patients need to be informed about the rare possi-
bility of a malignant disease despite accurate pre-operative
evaluation without signs of malignancy or pre-malignancy,
during pre-operative counseling. Additionally the necessity
of follow-up surgery, depending on the findings, has to be
pointed out. In case of a timely second operation, the
prognosis is shown to be very good. Only for a few pa-
tients, in case of leiomyosarcomas, prognosis is very bad;
however, this prognosis is generally very bad, even with
abdominal hysterectomy and no morcellation. Tumor stage
is the most important prognostic factor for all histological
types, with 5-year overall survival being 50–55 % for stage
I and 8–12 % for stage II–IV disease [29, 30].
Unfortunately in these cases no pre-operative diagnos-
tics are known to be predictive of the subsequent histo-
logical findings.
Although our results confirm the rare occurrence of
uterine sarcomas, improved diagnostic methods are nec-
essary to distinguish between malignant and benign my-
omas, as recommended by the AAGL. Furthermore,
criteria for the identification of high-risk groups must be
developed. This is only possible through data evaluation
from national and international cancer and sarcoma reg-
istries and prospective and retrospective multicenter stud-
ies to examine the prevalence and progression after
different treatment regimens, allowing a central evaluation
of the treatment outcomes in uterine sarcomas.
In the 195th statement the German Association for
Gynecology and Obstetrics (DGGG) quote an incidence
rate of uterus sarcomas of 1.32 in 100,000 women in
Germany in 2010 and of 1.3 in 100,000 woman in Bavaria
between 2002 and 2011 [31] for gynecologic morcellators.
Furthermore the DGGG emphasizes in this statement, that
all patients should be sufficiently informed about the po-
tential risk, advantages, disadvantages and alternatives (non-
operative, operative) during pre-operative counseling [31].
The German Society for Gynecological Endoscopy
(AGE) underlines that in many cases electric morcellation
is important for the treatment of symptomatic myomas.
This way the favorable treatment via minimally invasive
laparoscopic hysterectomy or organ-conserving myomec-
tomy instead of abdominal hysterectomy is possible in
many cases. Banishment of electric morcellation would
lead to a higher morbidity and mortality. However, all
patients have to be informed about the low probability of
malignant disease [32].
Conclusion
A very small incidence of sarcoma (0.06 %) and en-
dometrial carcinoma (0.07 %) were detected in 10,731
uteri morcellated after LASH. All patients should be in-
formed about the rare possibility of a malignant disease
during pre-operative counseling.
With a timely follow-up surgery according to the on-
cologic guidelines our data suggest a very good prognosis
in terms of survival after LASH with morcellation of ma-
lignant tumors in the uterus. Surgeons should not miss the
advantages of morcellation during laparoscopic surgery
given that there are no pre-malignancies or malignancies
detected pre-operatively.
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